Ray
Showing 1–2 of 2 transcripts.
- Milken Institute58 min
New Horizons for Accelerating Drug Repurposing
Dr. David Fajgenbaum, Ray, Kristen, Marianne Clancy, Christine Colvis
Hosted by TRiN and Faster Cures, this webinar featured experts from EveryCure, CURE HHT, and NCATS to examine strategies for accelerating the repurposing of existing drugs for rare diseases. Presenters detailed how AI-driven knowledge graphs and patient-led advocacy successfully navigated financial, intellectual property, and regulatory hurdles to secure approvals for conditions like Castleman's disease and Hereditary Hemorrhagic Telangiectasia. The session concluded with a consensus that generating clinical evidence and securing payment pathways are more critical than intellectual property protection for bringing generic therapies to new indications.
- Milken Institute1h 1m
Is There Mojo in M&A?
Robert Rankin, Jonathan Coslet, DA, Ray, Steven, Nick, Rosie Greer
A resurgence in global M&A volumes, projected to reach $3.5 trillion this year, is driven by robust financing liquidity and a strategic shift by corporate boards from balance sheet repair to growth-focused acquisitions. While Private Equity participation remains normalized at 5% of total volume, heavy consolidation is occurring in pharmaceuticals, banking, and real estate sectors as firms navigate regulatory constraints and activist investor pressures. This market activity is further shaped by a bifurcated cost of capital that favors investment-grade borrowers and small private credit funds, forcing large deals to rely on alternative capital structures.